You are invited to participate in an exclusive Catalyst Society Video Conference with a member of the Cure Alzheimer’s Fund Research Consortium. David Michael Holtzman, M.D. will share new insights about the disease pathology and the opportunities and challenges facing the Alzheimer’s scientific research community. The presentation will be followed by a Q&A. If we ...
May 4, 2017
***** On January 31, 2024, in a press release, Biogen announced that it is discontinuing production of Aduhelm. From the release, “The company will discontinue the development and commercialization of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study.” ***** On April 7, 2022, the ...
May 3, 2022
One of the challenges when developing treatments is finding a model system to test them in. Good model systems increase the likelihood that the treatments will be successful in human clinical trials, which are logistically challenging, long and expensive. To this end, our group and international collaborators have made two ...
January 31, 2024
January 30, 2024
January 30, 2024
SAN DIEGO, July 16, 2013 – Confirming an enzyme in the serine hyrdrolase family as a therapeutic target to slow and potentially reverse the effects of Down syndrome and Alzheimer’s disease is the goal of new research announced today by Abide Therapeutics, in collaboration with researchers at the University of ...
July 15, 2013
Supplemental Information for Senate Special Committee on Aging Hearing Introduction Alzheimer’s disease (AD), the most common form of dementia, was first described roughly one hundred years ago in Bavaria by Dr. Alois Alzheimer in his presentation of an early-onset (
August 20, 2009
“For someone with a background in molecular biology and neuroscience, this is like going into outer space.” SANGRAM SISODIA NEUROBIOLOGIST, UNIVERSITY OF CHICAGO In 2014, John Cryan, a professor at University College Cork in Ireland, attended a meeting in California about Alzheimer’s. He was not an expert on dementia. Instead, he ...
March 15, 2019
2019 This project recently established a more accurate and efficient model to identify fluorescent images generated by treating the Alzheimer’s in a Dish model with compounds that can clear accumulated phosphorylated tau. Meanwhile, 29 new candidate compounds recently going through clinical trials for various diseases were generated by in silico prediction ...
August 27, 2018
Below is the text from an article included on the Eureka blog which provides an overview of the need for a multi-pronged approach to stopping Alzheimer’s disease. The work of Dr.’s Rudy Tanzi and David Holtzman, and the late Stephen Wagner, of the Cure Alzheimer’s Fund Research Leadership Group, is ...
November 2, 2023
